Citations

Clear

16280 citation(s) found for "Yu, David".

Proton dose calculation with transformer: Transforming spot map to dose
Tang, Xueyan , Tseung, H. Wan Chan, Johnson, Jed E., Moseley, D.J., Tseung, Hok Wan Chan, Moseley, Doug J, Qian, Jing , Pepin, Mark D., Routman, David M. , Qian, Jing

Mayo Clinic

Medical Physics | March 31, 2025 | Volume: 52 | Issue: 6 | Pages: 4941-4952

10.1002/mp.17794 | PMID 40156258 Get It

Abstract Background Conventional proton dose calculation methods are either time‐ and resource‐intensive, like Monte Carlo (MC) simulations, or they sacrifice accuracy, as seen with analytical methods. This trade‐off between computational efficiency and accuracy highlights the need for improved dose calculation approaches in clinical settings. Purpose This study aims to develop a deep‐learning‐based model that calculates dose‐to‐water ( D W ) and dose‐to‐medium ( D M ) using patient anatomy and proton spot map (PSM), achieving approaching MC‐level accuracy with significantly reduced computation time. Additionally, the study seeks to generalize the model to different treatment sites using transfer learning. Methods A SwinUNetr model was developed using 259 four‐field prostate proton stereotactic body radiation therapy (SBRT) plans to calculate patient‐specific D W and D M distributions from CT and projected PSM (PPSM). The PPSM was created by projecting PSM into the CT scans using spot coordinates, stopping power ratio, beam divergence, and water‐equivalent thickness. Fine‐tuning was then performed for the central nervous system (CNS) site using 84 CNS plans. The model's accuracy was evaluated against MC simulation benchmarks using mean absolute error (MAE), gamma analysis (2% local dose difference, 2‐mm distance‐to‐agreement, 10% low dose threshold), and relevant clinical indices on the test dataset. Results The trained model achieved a single‐field dose calculation time of 0.07 s on a Nvidia‐A100 GPU, over 100 times faster than MC simulators. For the prostate site, the best‐performing model showed an average MAE of 0.26 ± 0.17 Gy and a gamma index of 92.2% ± 3.1% in dose regions above 10% of the maximum dose for D W calculations, and an MAE of 0.30 ± 0.19 Gy with a gamma index of 89.7% ± 3.9% for D M calculations. After transfer learning for CNS plans, the model achieved an MAE of 0.49 ± 0.24 Gy and a gamma index of 90.1% ± 2.7% for D W computations, and an MAE of 0.47 ± 0.25 Gy with a gamma index of 85.4% ± 7.1% for D M computations. Conclusions The SwinUNetr model provides an efficient and accurate method for computing dose distributions in proton therapy. It also opens the possibility of reverse‐engineering PSM from D W , potentially speeding up treatment planning while maintaining accuracy.
Challenges of Ventilator Procurement and Distribution in the ICU During the COVID-19 Pandemic: A Scoping Review
Anjos, Gabriele A. dos, ZEC, SARA NAAS, Zambrano, Claudia Castillo , Rovati, Lucrezia , Dong, Yue , Nemet, Marko , Dos Anjos, Gabriele A, Zec, Sara N, Zambrano, Claudia C, Dong, Yue , Wang, David , Hieu, Truong Hong

Mayo Clinic

Critical Care Explorations | March 30, 2025 | Volume: 7 | Issue: 4 | Pages: e1248

10.1097/cce.0000000000001248 | PMID 40153548 Get It

OBJECTIVES: The goal of this scoping review was to review some of the challenges hospitals faced in dealing with the shortage of ventilators during the COVID-19 pandemic and the solutions they were able to implement or suggested. By highlighting these problems and solutions, we hope this review can catalyze further discussions about how to better prepare for future pandemics and medical supply shortages. DATA SOURCES: A comprehensive search strategy using identifying key words was applied to several different databases to procure relevant literature. STUDY SELECTION: Four thousand two hundred fifty-nine studies were found in the initial search. Inclusion and exclusion criteria were created and applied to screen studies. Included studies focused on the supply and distribution of ventilators during the COVID-19 pandemic. In the case where reviewers disagreed about whether a study should be included, a third reviewer acted as a tie-breaker. DATA EXTRACTION: Thirty-three studies were included for final data extraction. Two independent reviewers collected various data points from these studies, including the main challenges discussed by the authors, the level of ventilator shortage being addressed, whether ventilator sharing was discussed, and the limitations of the study. DATA SYNTHESIS: A third reviewer compared the collected data and decided on the results. CONCLUSIONS: Some of the common solutions for the ventilator shortage discussed included augmenting overall ventilator supply through increased production, transporting ventilators between hospitals, ventilator sharing, designing new ventilators, and repurposing other resources to help address shortages of supplies.
A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021
Jacobs, Jeremy W. , Adkins, Brian D. , Stanek, C , Stephens, Laura D. , Daou, Laetitia , Siniard, Rance C. , Wallace, Lisa R., Duque, Miriam Andrea, Wu, Yanyun , Aljuboori, Omar , Harrington, Thomas J., Byrnes, Diana M. , Eichbaum, Quentin , Klapper, Ellen, Klein, Monica S., Alkhateb, Rahaf, Powers, Amy, Webb, Christopher B. , Yates, Sean G. , Bloch, Evan M. , Adkins, Brian D. , Booth, Garrett , Stanek, Caroline G , Grossman, Brenda J , Stephens, Laura , Crowe, Elizabeth P , Marques, Marisa B , Yamada, Chisa , Juskewitch, Justin E , Perez-Alvarez, Ingrid , Parsons, Meredith G , Schlueter, Annette J , Tormey, Christopher A , Yates, Sean G , Bloch, Evan M , Raval, Jay S , Jacobs, Jeremy W , Adkins, Brian David , Adkins, Brian D. , Booth, Garrett S. , Allen, Elizabeth S. , Grossman, Brenda J. , Marques, Marisa B. , Yamada, Chisa , Villalba, Cristina A. Figueroa , Juskewitch, Justin E. , Aldarweesh, Fatima , Parsons, Meredith G , Schlueter, Annette J. , Tormey, Christopher A. , Wheeler, Allison P. , Raval, Jay S.

Mayo Clinic

Journal of Clinical Apheresis | March 30, 2025 | Volume: 40 | Issue: 2 | Pages: No page available

10.1002/jca.70017 | PMID 40145682 Get It

ABSTRACTImmune thrombotic thrombocytopenic purpura (iTTP) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular occlusion secondary to acquired ADAMTS13 deficiency. Contemporary data regarding iTTP treatment practices in the US, including the use of caplacizumab, are lacking. We aimed to characterize the demographics and therapies, including medications and apheresis practices, in patients with iTTP in the US. We retrospectively analyzed iTTP cases at 15 sites in the US that provide comprehensive care for patients with iTTP. The time‐period assessed was from January 1, 2017 to December 31, 2021. Our primary objective was to analyze data by iTTP episode, inclusive of initial episodes and relapses. A total of 390 iTTP episodes were reported for 280 unique individuals (187 females, 93 males). Thirty‐day mortality was 3.7% (14/374), and 6‐month mortality was 7.4% (27/367). TPE details were reported for 343 episodes, among which 261 underwent at least one procedure (median 6, IQR 3–11). Among the 261 episodes with at least one therapeutic plasma exchange (TPE) performed, 82.0% (214/261) used only plasma. Caplacizumab was used either alone or in combination with other agents in 43 (11.0%) episodes. Management strategies for iTTP remain varied across centers in the US, with a variety of combinations for TPE replacement fluids and therapeutic agents, as well as limited use of caplacizumab. Further research and standardization of treatment regimens may further reduce mortality in this condition.
Deep learning for echocardiographic assessment and risk stratification of aortic, mitral, and tricuspid regurgitation: the DELINEATE-regurgitation study
Long, Aaron S. , Finer, Joshua , Hartzel, Dustin N. , Jing, Linyuan, Ruhl, Jeffrey , vanMaanen, David P., Elnabawi, Youssef , Metser, Gil , Duffy, Eamon , Mawson, Thomas, Tat, Emily , Kumaraiah, Deepa, Devereux, Richard B., Homma, Shunichi, Leon, Martin B. , Hahn, Rebecca T , Poterucha, Timothy J. , Ruhl, Jeffrey , Hahn, Rebecca T , Elias, Pierre , Poterucha, Timothy Joseph , Long, Aaron, Hartman, Heidi S. , Jing, Linyuan , Kelsey, Chris R. , Rocha, Daniel , Haggerty, Christopher M. , Maurer, Matthew J. , Einstein, Andrew Jeffrey , Beecy, Ashley , Devereux, Richard B.

Mayo Clinic

European Heart Journal | March 29, 2025 | Volume: 46 | Issue: 28 | Pages: 2780-2791

10.1093/eurheartj/ehaf248 | PMID 40156921 Get It

Abstract Background and Aims Classification and risk stratification in aortic (AR), mitral (MR), and tricuspid regurgitation (TR) remains a significant clinical challenge. This study aimed to develop an artificial intelligence (AI) system to assess valvular regurgitation and stratify MR-progression risk. Methods Using transthoracic echocardiograms (TTEs) at two sites (internal development/test, external test), the DELINEATE-Regurgitation system was developed to classify AR, MR, and TR severity using colour Doppler videos. Methods of summating video-level classifications into study-level predictions were tested, comparing single-view with multiview approaches integrating predictions across multiple videos. Model agreement with cardiologists was assessed by weighted kappa. A separate AI system (DELINEATE-MR-Progression) analysing colour Doppler videos was developed to predict which patients with mild, mild–moderate, and moderate MR were most likely to progress to moderate–severe or severe MR with analysis by Kaplan–Meier and Cox proportional hazards models. Results A total of 71 660 TTEs with 1 203 980 colour Doppler videos were included. The weighted kappa in internal/external test sets for regurgitation classification was 0.81/0.76 for AR, 0.76/0.72 for MR, and 0.73/0.64 for TR using a multiview approach taking all colour Doppler videos in a study, demonstrating substantial agreement with cardiologist interpretation with superiority of multiview over single view approaches. In the progression analysis, the AI score stratified MR-progression risk even when controlled for clinical factors known to be associated with MR progression [internal test set hazard ratio 4.1 (95% confidence interval 2.5–6.6)]. Conclusions An AI system can accurately classify AR, MR, and TR and predict MR progression beyond currently known risk factors.
Selective Elimination of Breast Surgery for Invasive Breast Cancer
Kuerer, Henry M. , Valero, V, Krishnamurthy, Savitri, Diego, Emilia J. , Lin, Heather , Shen, Yu , Mitchell, Melissa P. , Yang, Wei , Group, Exceptional Responders Study, Moseley, Tanya W. , Leung, Jessica WT, Huang, Monica L. , Parra, Raquel FD van la, Teshome, Mediget , Hwang, Rosa F. , Miggins, Makesha, Piotrowski, Matthew J., Refinetti, Ana P, Ehlers, Richard A., Mouabbi, Jason , Colen, Jessica Suarez, Loveland‐Jones, Catherine, Lesnikowski, Beth Ann, Samiian, Laila, Chong, Clayton, Black, Dalliah M. , Desyder, Sarah M, Nguyen, Tuyen , Smith, Benjamin D. , Krishnamurthy, Savitri , Johnson, Helen Margaret , Lucci, Anthony , Shaitelman, Simona Flora , Boughey, Judy C. , White, Richard L., Hunt, Kelly K. , Rauch, Gaiane M. , Group, Exceptional Responders Study, Candelaria, Rosalind P. , Adrada, Beatriz E. , Arribas, Elsa , Ramirez, David Luis , Sun, Susie X.

Mayo Clinic

JAMA Oncology | March 28, 2025 | Volume: 11 | Issue: 5 | Pages: 529

10.1001/jamaoncol.2025.0207 | PMID 40152443 Get It

Importance Neoadjuvant systemic therapy (NST) has been associated with pathologic complete response (pCR) in up to 60% of breast cancers (BCs). The findings of this trial question the necessity of surgery. Objective To report preplanned 5-year efficacy outcomes evaluating radiotherapy alone without breast surgery in patients selected with image-guided vacuum assisted biopsy (VAB). Design, Setting, and Participants This single-arm, prospective, phase 2 nonrandomized clinical trial was conducted at 7 US medical centers and included women 40 years or older with cT1-2N0-1M0 ERBB2 -positive (formerly HER2 -positive) or triple-negative invasive BC who showed residual breast lesions after NST of less than 2 cm on imaging. Enrollment was from March 6, 2017, to November 9, 2021. Data analysis was from October to December 2024. Intervention Image-guided VAB of the tumor bed (9G with a minimum of 12 cores) was performed after standard NST. Patients with clinically node-negative disease at diagnosis and no residual cancer in the breast on post-NST VAB underwent whole-breast radiotherapy with a boost without breast or axillary surgery. Patients with initial documented nodal disease and a breast pCR on VAB underwent targeted axillary dissection, while those with residual cancer when undergoing VAB had standard breast and axillary surgery. Patients were monitored with physical examinations and mammography every 6 months. Main Outcome Measures The primary outcome was ipsilateral breast tumor recurrence. Results Fifty patients (median [IQR] age, 62 [55-77] years) were enrolled and underwent post-NST VAB. Twenty-nine (58%) and 21 (42%) patients had ERBB2 -positive and triple-negative invasive BC, respectively. Breast pCR on VAB was identified in 31 patients (62%; 95% CI, 47.2%-75.34%), and axillary pCR was identified among all 8 patients with initial nodal metastases and breast pCR on VAB who underwent targeted axillary dissection. At a median follow-up of 55.4 (IQR, 44.0-63.5) months, the ipsilateral breast tumor recurrence rate was 0%, and disease-free and overall survival rates were 100% for patients without breast surgery. Conclusions and Relevance The results of this nonrandomized clinical trial that reported preplanned 5-year outcomes suggest that omission of breast surgery in select patients after NST may be feasible, with no recurrences seen. More confirmatory studies are necessary before this new approach alters surgical practice. Trial Registration ClinicalTrials.gov Identifier: NCT02945579
The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program
Hanauer, Stephen B. , Torres, Esther A. , Aragon-Han, Patricia, Chapman, J. Casey, Arai, Ronen, Butnariu, Mandalina, Lee, Thomas C., Rabizadeh, Shervin , Check, Morgan, Hashash, Jana G. , Meister, Thomas, Yen, Eugene F. , Kinnucan, Jami , Ziring, David , Shaposhnikov, Rimma, Sinh, Preetika , Qazi, Taha , Yarur, Andrés , Monzur, Farah , Abraham, Bincy , Lee, Thomas C , Hashash, Jana G , Sinh, Preetika , Abraham, Bincy P , Yarur, Andres J , Hanauer, Stephen B , Swaminath, Arun C. , Butnariu, Mandalina, Barrett, Terrence A. , Stein, Daniel J., Shaposhnikov, Rimma, Dervieux, Thierry

Mayo Clinic

Pharmaceutics | March 28, 2025 | Volume: 17 | Issue: 4 | Pages: 428

10.3390/pharmaceutics17040428 | PMID 40284422 Get It

Background/Objectives: This study aimed to establish the clinical utility of a therapeutic drug monitoring (TDM)-supported, model-informed precision dosing (MIPD) approach (precision-guided dosing [PGD]) by assessing the impact of pharmacokinetic (clearance [CL]) and clinical laboratory parameters on adalimumab (ADA) dosage adjustments during maintenance therapy for inflammatory bowel disease (IBD). Methods: In the EMPOWER study, blood was collected at any time post-ADA injection. Pharmacokinetic (PK) testing was conducted in an accredited lab. Inputs for the PGD test included ADA concentrations, antibodies to ADA, albumin levels, and the current dosing regimen. CL was calculated using nonlinear mixed-effect models. Results were reported to health care providers (HCPs) within 3 days. HCPs’ treatment decisions were recorded and classified as treatment reduction, continuation, intensification, or ADA discontinuation. The physician global assessment (PGA) of disease activity was collected. Relationships between drug concentrations, CL, disease activity, and physician decision-making were assessed using logistic regression. Results: A total of 213 cases were assessed by 21 HCPs. ADA treatment was intensified in 24% and discontinued in 13% of cases. An ADA concentration ≤ 10 μg/mL was associated with a 23.7-fold and 3.0-fold higher likelihood of therapy intensification and PGA > 0, respectively, compared to concentrations > 10 μg/mL. An ADA concentration < 5 μg/mL was associated with a 3.3-fold higher likelihood of treatment discontinuation. CL ≥ 0.318 L/day was associated with a 10.4-fold higher likelihood of therapy intensification. Higher CL (>0.8 L/day) was associated with a 3.5-fold and 4.2-fold higher likelihood of treatment discontinuation and PGA > 0, respectively. Conclusions: PGD enables earlier and precise optimization of ADA dosing by predicting trough levels at any time during the therapy cycle. Optimized dosing to achieve target ADA concentrations and low clearance is crucial to mitigate therapy discontinuation and active disease in IBD patients.
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Borate, Uma , Pugh, Kelly , Waller, Allyson, Welkie, Rina Li , Huang, Ying , Stahl, Maximilian , Platzbecker, Uwe , Wei, Andrew H. , Buckstein, Rena , Hasserjian, Robert P. , Fenaux, Pierre , Sallman, David A. , Nimer, Stephen D. , Little, Richard F. , Garcia‐Manero, Guillermo , Odenike, Olatoyosi, Kim, Tae Kon , Greenberg, Peter L. , Xu, Mina L. , Patnaik, Mrinal M. , Padron, Eric , Gore, Steven D. , Churpek, Jane E. , Bennett, John M., Brunner, Andrew M. , Zeidan, Amer M., Zeidan, Amer M. , Platzbecker, Uwe , Sekeres, Mikkael A , Wei, Andrew H , Roboz, Gail J , Loghavi, Sanam , Hasserjian, Robert P , Sallman, David A , Hourigan, Christopher S , Della Porta, Matteo Giovanni , Little, Richard F , Santini, Valeria , Taylor, Justin , Kim, Tae Kon , Halene, Stephanie , Komrokji, Rami S , Griffiths, Elizabeth A. , Greenberg, Peter L , Xie, Zhuoer , Sanz, Guillermo F , Patnaik, Mrinal , Carraway, Hetty E. , Boultwood, Jacqueline , Daver, Naval , Zeidan, Amer M , Churpek, Jane E , Bewersdorf, Jan Philipp , Dezern, Amy Elizabeth , Sekeres, Mikkael A. , Roboz, Gail J. , Savona, Michael R. , Loghavi, Sanam , Hourigan, Christopher S. , Santini, Valeria , Efficace, Fabio , Odenike, Olatoyosi , Komrokji, Rami S. , Xie, Zhuoer , Bejar, Rafael , Sanz, Guillermo , Figueroa, María E. , Abdel‐Wahab, Omar , Starczynowski, Daniel T. , Boultwood, Jacqueline , Daver, Naval , Majeti, Ravindra , List, Alan F. , Brunner, Andrew M., Churpek, Jane

Mayo Clinic

Blood | March 27, 2025 | Volume: 145 | Issue: 13 | Pages: 1369-1381

10.1182/blood.2023023717 | PMID 40146152 Get It

Abstract Excessively restrictive inclusion and exclusion criteria in clinical trials are one of many barriers to clinical trial enrollment for patients with myelodysplastic syndromes/neoplasms (MDSs). Many organizations are developing efforts to increase clinical trial eligibility; yet, several recent publications focused on patients with MDS suggest that many patients with this disease may be excluded from clinical trials unnecessarily. Clinical trial eligibility should reflect the phase of the study and risks of the agent being studied. Phase 3 trials should be less restrictive than early-phase trials to represent the real-world population as closely as possible. We hypothesize that many clinical trials, particularly phase 3 trials, have unnecessarily restrictive eligibility criteria. This study aims to evaluate the most common eligibility criteria according to phase of trial and to determine whether criteria correspond with drug safety signals. We identified MDS clinical trials registered on ClinicalTrials.gov from 1 January 2000 to 1 September 2023 and analyzed the eligibility criteria of 191 therapeutic MDS trials. We found that categorical inclusion and exclusion criteria are remarkably similar in representation across trial phases. Additionally, only 13% of trials are concordant with drug safety signals, suggesting that the eligibility criteria are often arbitrary. On behalf of the icMDS (International Consortium for Myelodysplastic Syndromes), an association of international MDS experts, we provide a position statement on restrictive eligibility criteria for MDS clinical trials that should be avoided with the aim of removing barriers to clinical trial enrollment.
Factors Associated With Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection
Mandel, Daniel , Shu, Liqi , Chang, Christopher , JACK, N , Henninger, Nils , Muppa, Jayachandra , Affan, Muhammad , Lodhi, Omair ul haq , Heldner, Mirjam R. , Omran, Setareh Salehi , Crandall, Ross , Lester, Evan, Araúz, Antonio , Boulanger, Marion , Sousa, João André , Barata, Vasco , Castro‐Chaves, Paulo , Brito, Maria Teresa , Khan, Muhib , Mallick, Dania, Rothstein, Aaron , Khazaal, Ossama , Traenka, Christopher , Sousa, Diana Aguiar de , Soares, Mafalda , Rosa, Sara , Zhou, Lily , Gandhi, Preet , Field, Thalia S. , Mancini, Steven, Pan, Kelly , Dantu, Vishnu , Baumgartner, Karl , Nolte, Christian H. , Choi, Richard , Macdonald, J , Ghannam, Malik , Almajali, Mohammad , Sanchez, Sebastian , Zine-Eddine, Fayçal, Poppe, Alexandre Y. , Fonseca, Ana Catarina , Baptista, Maria Fortuna , Cruz, Diana , Marco, Giovanna De , Griffin, Kim J. , Kuohn, Lindsey , Frontera, Jennifer , Amar, Jordan , Grisendi, Ilaria , Nzwalo, Hipólito , Liebeskind, David S. , Molaie, Amir , Cavalier, Annie, Kam, Wayneho , Grory, Brian Mac , Kasab, Sami Al , Eltatawy, Ali , Chervak, Lina , Rivas, Roberto Chulluncuy, Bakradze, Ekaterina , Tran, Thanh Lam , Ortiz-Garcia, Jorge , Muddasani, Varsha , Vishnu, Venugopalan Y. , Yaddanapudi, Sridhara , Adams, L, Browngoehl, Abigail, Dunston, Randy, Lynch, Zachary, Penckofer, Mary , Mayer, Silvia, Zubair, Adeel , Cheng, Yee Kuang, Ferreira, Vítor Mendes , Asad, Syed Daniyal , Sarwat, Zoha, Balabhadra, Anvesh , Patel, Shivam , Secchi, Thaís , Mantovani, Gabriel Paulo , Krishnaiah, Balaji , Lingam, Sivani, Khasiyev, Farid , Linares, Guillermo , Mannino, Marina , Terruso, Valeria, Vassilopoulou, Sofia , Tentolouris-Piperas, Vasileios , Wall, Victor Carrasco , Indraswari, Fransisca , Jamal, Sleiman El , Liu, Shilin, Alvi, Muhammad , Sarvath, Mohammed, Kass‐Hout, Tareq , Shi, Feina , Zhang, Jinhua , Said, Jamil , Mongare, Newnex, Sen, Shayak, Ghani, Mohammad R , Elnazeir, Marwa , Xiao, Han , Khan, Farhan , Mohammadzadeh, Nahid , Furie, Karen L. , Mandel, Daniel M , Jack, Naomi , Leon Guerrero, Christopher R , Henninger, Nils , Muppa, Jayachandra , Heldner, Mirjam R , Antonenko, Kateryna , Seiffge, David , Arnold, Marcel , Salehi Omran, Setareh , Crandall, Ross , Lopez Mena, Diego , Arauz, Antonio , Boulanger, Marion , Touzé, Emmanuel , Sousa, Joao Andre , Sargento-Freitas, Joao , Barata, Vasco , Castro-Chaves, Paulo , Brito, Maria Teresa , Khan, Muhib , Rothstein, Aaron , Khazaal, Ossama , Kaufman, Josefin E , Engelter, Stefan T , Traenka, Christopher , Aguiar de Sousa, Diana , Soares, Mafalda , Rosa, Sara , Zhou, Lily W , Gandhi, Preet , Field, Thalia S , Metanis, Issa , Leker, Ronen R , Dantu, Vishnu , Baumgartner, Karl , Burton, Tina , von Rennenberg, Regina , Nolte, Christian H , Choi, Richard , MacDonald, Jason , Bavarsad Shahripour, Reza , Guo, Xiaofan , Ghannam, Malik , Almajali, Mohammad , Samaniego, Edgar A , Sanchez, Sebastian , Rioux, Bastien , Poppe, Alexandre , Fonseca, Ana Catarina , Fortuna Baptista, Maria , Cruz, Diana , Romoli, Michele , Longoni, Marco , Keser, Zafer , Kuohn, Lindsey , Frontera, Jennifer , Giles, James , Zedde, Marialuisa , Pascarella, Rosario , Grisendi, Ilaria , Nzwalo, Hipolito , Liebeskind, David S. , Molaie, Amir , Kam, Wayneho , Mac Grory, Brian , Al Kasab, Sami , Anadani, Mohammad , Kicielinski, Kimberly , Eltatawy, Ali , Chervak, Lina , Aziz, Yasmin , Bakradze, Ekaterina , Rodrigo Gisbert, Marc , Requena, Manuel , Saleh Velez, Faddi , Garcia, Jorge Ortiz , Muddasani, Varsha , de Havenon, Adam H , Vishnu, Venugopalan Y , Adams, Latasha , Ranasinghe, Tamra , Penckofer, Mary , Siegler, James E , Mayer, Silvia , Willey, Joshua , Zubair, Adeel , Cheng, Yee Kuang , Sharma, Richa , Marto, João Pedro , Mendes Ferreira, Vítor , Klein, Piers , Nguyen, Thanh N , Asad, Syed Daniyal , Balabhadra, Anvesh , Martins, Sheila , Mantovani, Gabriel , Kim, Young Dae , Krishnaiah, Balaji , Elangovan, Cheran , Qureshi, Abid Y , Fridman, Sebastian , Alvarado-Bolanos, Alonso , Khasiyev, Farid , Linares, Guillermo , Mannino, Marina , Terruso, Valeria , Vassilopoulou, Sofia , Tentolouris-Piperas, Vasileios , Martinez Marino, Manuel , Carrasco Wall, Victor , Indraswari, Fransisca , El Jamal, Sleiman , Liu, Shilin , Sarvath, Mohammed , Morsi, Rami Z , Kass-Hout, Tareq , Shi, Feina , Zhang, Jinhua , Sokhi, Dilraj , Simpkins, Alexis N , Ghani, Mohammad , Elnazeir, Marwa , Xiao, Han , Khan, Farhan , Stretz, Christoph , Goldstein, Eric D , Furie, Karen L , Yaghi, Shadi , Seiffge, David , Nehme, Ahmad , Sargento‐Freitas, João , Kaufmann, Josefin E. , Engelter, Stefan T. , Metanis, Issa , Shahripour, Reza Bavarsad , Guo, Xiaofan , Keser, Zafer , Giles, James , Zedde, Marialuisa , Pascarella, Rosario , Aziz, Yasmin , Rodrigo‐Gisbert, Marc , Requena, Manuel , Velez, Faddi G. Saleh , Havenon, Adam de , Ranasinghe, Tamra , Siegler, James E. , Sharma, Richa , Marto, João Pedro , Klein, Piers , Nguyen, Thanh N. , Kim, Young Dae , Elangovan, Cheran , Alvarado‐Bolaños, Alonso , Martínez-Marino, Manuel , Ali, Farman, Morsi, Rami Z. , Simpkins, Alexis N. , Gomez, Roberto, Sen, Shayak, Kala, Narendra , Stretz, Christoph , Goldstein, Eric , Yaghi, Shadi

Mayo Clinic

Stroke | March 27, 2025 | Volume: 56 | Issue: 6 | Pages: 1413-1421

10.1161/strokeaha.124.048215 | PMID 40143807 Get It

BACKGROUND: Patients presenting with cervical artery dissection (CAD) are at risk for subsequent ischemic events. We aimed to identify characteristics that are associated with increased risk of ischemic stroke after initial presentation of CAD and to evaluate the differential impact of anticoagulant versus antiplatelet therapy in these high-risk individuals. METHODS: This was a preplanned secondary analysis of the STOP-CAD study (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection), a multicenter international retrospective observational study (63 sites from 16 countries in North America, South America, Europe, Asia, and Africa) that included patients with CAD predominantly between January 2015 and June 2022. The primary outcome was subsequent ischemic stroke by day 180 after diagnosis. Clinical and imaging variables were compared between those with versus without subsequent ischemic stroke. Significant factors associated with subsequent stroke risk were identified using stepwise Cox regression. Associations between subsequent ischemic stroke risk and antithrombotic therapy type (anticoagulation versus antiplatelets) among patients with identified risk factors were explored using adjusted Cox regression. RESULTS: In all, 4023 patients (mean age was 47.4 years; 44.5% were women) were included. By day 180, subsequent ischemic stroke occurred in 5.3% of the cohort. In adjusted Cox regression, factors associated with increased risk of subsequent ischemic stroke were prior history of ischemic stroke (adjusted hazard ratio [aHR], 7.31 [95% CI, 1.61–33.13]; P =0.010), presentation within 7 days from first symptoms (aHR, 3.04 [95% CI, 1.04–8.91]; P =0.043), infarct on baseline imaging (aHR, 9.85 [95% CI, 3.65–26.58]; P <0.001), and occlusive dissection (aHR, 2.34 [95% CI, 1.03–5.34]; P =0.043). Only patients with occlusive dissection demonstrated a reduced risk of subsequent ischemic stroke when treated with anticoagulation versus antiplatelets (aHR, 0.36 [95% CI, 0.16–0.80]; P =0.01). CONCLUSIONS: In this post hoc analysis of the STOP-CAD study, several factors associated with subsequent ischemic stroke were identified among patients with CAD. Furthermore, we identified a potential benefit of anticoagulation in patients with CAD with occlusive dissection. These findings require validation by meta-analyses of prior studies to formulate optimal treatment strategies for specific high-risk CAD subgroups.
Targeting senescence in Amyotrophic Lateral Sclerosis: senolytic treatment improves neuromuscular function and preserves cortical excitability in a TDP-43Q331K mouse model.
Viteri*, Jose A., Kerr*, Nathan R., Brennan*, Charles D., Kick, Grace Robinson , Wang, Meifang , Snyder, Harper K., Moore, Peter J., Darvishi, Fereshteh B. , Dashtmian, Anna R. , Ayyagari, Sindhuja N. , Rich, Kelly , Arnold, W. David, Zhu, Yi , Viteri*, Jose A., Kerr*, Nathan R., Brennan*, Charles D., Ketabforoush, Arsh Haj Mohamad Ebrahim , Snyder, Harper K., Moore, Peter J., Zhu, Yi , Arnold, W. David

Mayo Clinic

No container title available | March 27, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6081213/v1 | PMID 40196013 Get It

Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder marked by progressive motor neuron degeneration in the primary motor cortex (PMC) and spinal cord. Aging is a key factor in ALS onset and progression, with evidence suggesting that biological aging—a process involving cellular decline— far outpaces chronological aging in ALS. This promotes senescent cell accumulation—marked by irreversible cell-cycle arrest, impaired apoptosis, and chronic inflammation—disrupting tissue homeostasis and impairing neuronal support functions. Thus, targeting senescence presents a novel therapeutic strategy for ALS. Here, we investigated the senolytic combination Dasatinib and Quercetin (D&Q) in TDP-43 Q331K ALS mice. D&Q improved neuromuscular function and reduced plasma neurofilament light chain, a biomarker of axonal damage. The most pronounced improvement was the improved cortical excitability, accompanied by reductions in senescence and TDP-43 in the PMC. These findings highlight the potential of senolytics to mitigate ALS-related dysfunction, supporting their viability as a therapeutic strategy. *Jose A. Viteriab, Nathan R. Kerrab, and Charles D. Brennana are co-first authors.